title: Testimony from the bedside: from Coley's toxins to targeted immunotherapy.
abstract: A new clinical study reported in the New England Journal of Medicine unveils the long-awaited outcome of anti-CTLA-4 therapy for melanoma. It provides grounds for continued enthusiasm for cancer immunotherapy, deepens our thoughts on underlying mechanisms, and suggests exciting next steps.
authors.affiliation: Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Cutaneous Biology Research Center, Boston, MA 02114, USA.
authors.forename: Jin Mo
authors.initials: JM
authors.lastname: Park
authors.forename: David E
authors.initials: DE
authors.lastname: Fisher